Sobi has narrowed its focus to haematology and immunology, shedding staff and R&D projects in other areas whilst taking full control of a drug it licenses from Novimmune.
Merck & Co/MSD has agreed to buy privately held biotech Tilos Therapeutics for up to $773 million, its third pipeline-boosting deal in a little over four months.
Swiss pharma Novartis is to pay up to $1 billion to Galapagos and MorphoSys for exclusive rights to a skin drug, which will further strengthen Novartis’s leadership position in the immunolo
